Lilly’s R&D whirlwind — what the large pharma has taken in and what it’s dropped
Eli Lilly reported a 39% year-over-year revenue increase to $24.4B in Q3, driven by obesity drugs Mounjaro and Zepbound. Analysts project strong future growth, with RBC Capital Markets raising its 2026 revenue forecast to $91.2B. Lilly is diversifying its pipeline with acquisitions and investments, including psychedelic-based treatments and cancer therapies, but has faced setbacks in gene therapy and other programs.
How this was made
The 30-second read
Why it matters
The disclosed spend and program drops introduce short‑term risk but do not fundamentally alter the growth narrative centered on obesity therapeutics.
Market read
Provides fresh data on Lilly's R&D allocation and pipeline adjustments, useful for investors monitoring biotech risk and growth balance.
What to watch
The $18.2 billion spend signals aggressive expansion; future acquisitions may offset current program losses.
Background
Eli Lilly's Q3 results showed 39% revenue growth driven by GLP‑1 obesity drugs, while the company disclosed sizable R&D spend and multiple pipeline terminations.
Ticker impact
Lilly disclosed $18.2 billion spent on business development and the discontinuation of several gene‑therapy and autoimmune programs in its Q3 filing.
modest downside pressure as investors weigh program drops against obesity‑drug momentum
The article provides new quantitative spend data and program terminations, which could cause short‑term sell‑off, but the core revenue engine remains strong.
Market effects
Highlights continued consolidation in biotech M&A and the challenges of gene‑therapy development, relevant for peers in pharma R&D.
U.S. biotech sector may see slight repricing of pipeline risk premiums.
Limited; primarily affects U.S. large‑cap pharma investors.
Counterpoint
Program cuts could free capital for higher‑margin opportunities, potentially boosting margins over the next year.
Key entities
- companyEli Lilly (LLY)
Large‑cap U.S. pharmaceutical firm
